You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia

Article Text

Article menu
Download PDFPDF
Therapeutics
Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia

http://dx.doi.org/10.1136/ebmh.10.2.57

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715–23.OpenUrlCrossRefPubMedWeb of Science

    Q Is clozapine more effective than other second-generation antipsychotics for people with resistant schizophrenia?

    METHODS

    Embedded ImageDesign:

    Randomised controlled trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Single blind (assessors blinded).

    Embedded ImageFollow-up period:

    Twelve months.

    Embedded ImageSetting:

    Five centres, UK; time period not stated.

    Embedded ImagePatients:

    136 adults (18–65 years old) with DSM-IV schizophrenia, schizoaffective or delusional disorder and poor clinical response to at least two other treatments. Exclusions: neuroleptic malignant disorder, substance misuse or medical disorder responsible for psychotic symptoms.

    Embedded ImageIntervention:

    Clozapine (end dose range 100–600 mg/day; mean end dose 333 mg/day) or other second-generation antipsychotic (amisulpride 600–800 mg/day (mean 683 mg/day), olanzapine 10–30 mg/day …

    View Full Text

    Footnotes

    • For correspondence: Shôn W Lewis, University of Manchester, Manchester, UK; shon.lewis{at}manchester.ac.uk

    • Source of funding: NHS Technology Assessment Program, UK.